A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Flutamide has been found to be equal to slightly more potent than cyproterone acetate and substantially more potent than spironolactone as an antiandrogen in bioassays. This is in spite of the fact that hydroxyflutamide has on the order of 10-fold lower affinity for the AR relative to cyproterone acetate. Hydroxyflutamide shows about 2- to 4-fold lower affinity for the rat and human AR than does bicalutamide. In addition, whereas bicalutamide has an elimination half-life of around 6 days, hydroxyflutamide has an elimination half-life of only 8 to 10 hours, a roughly 17-fold difference. In accordance, at dosages of 50 mg/day bicalutamide and 750 mg/day flutamide (a 15-fold difference), circulating levels of flutamide at steady-state have been found to be approximately 7.5-fold lower than those of bicalutamide. Moreover, whereas flutamide at this dosage has been found to produce a 75% reduction in prostate-specific antigen levels in men with prostate cancer, a fall of 90% has been demonstrated with this dosage of bicalutamide. In accordance, 50 mg/day bicalutamide has been found to possess equivalent or superior effectiveness to 750 mg/day flutamide in a large clinical trial for prostate cancer. Also, bicalutamide has been shown to be 5-fold more potent than flutamide in rats and 50-fold more potent than flutamide in dogs. Taken together, flutamide appears to be a considerably less potent and efficacious antiandrogen than is bicalutamide.
Like CD38, CD157 is a member of the ADP-ribosyl cyclase family of enzymes that catalyze the formation of cADPR from NAD+, although CD157 is a much weaker catalyst than CD38. The SARM1 enzyme also catalyzes the formation of cADPR from NAD+, but SARM1 elevates cADPR much more efficiently than CD38.
For centuries, the Danes and Saxons had regarded each other as kindred peoples, sharing the same belief in the Germanic pantheon and frequently intermarrying, especially among the elite. Thus, the defeated Saxon warleader Widukind sought refuge with his father-in-law, Danish king Sigfred. The Royal Frankish Annals mentions that Widukind received substantial aid from Sigfred, though the exact nature of this aid is not explicitly stated. However, the chronicles do note that Sigfred and Charlemagne brokered a peace agreement some years later, indicating that Sigfred, upon hearing Widukind's plea, may have mustered his army and joined the war on the side of the Saxons. In response to the Danes' involvement in the war, Charlemagne seems to have recruited the Obotrites by promising them the Saxon portion of Holstein. This alliance with Charlemagne shifted the balance of power in the region. In 782, after another defeat of the Saxons, Charlemagne ordered the mass execution of 4,500 Saxons, an atrocity that became known as the Massacre of Verden. Following this brutal act, Charlemagne was nicknamed the "Butcher of Saxons" or "Saxonslaughterer." In 796, despite Saxony being fully under Frankish rule, the Saxons rose once more, supported by the Danes. The rebellion was triggered by the forced conscription of Saxons for the Frankish wars against the Avars. Moreover, Charlemagne, in alliance with the Obotrites, planned to subjugate the Danes, now led by King Gudfred Sigfredson. However, Gudfred struck first.
Sources: en.wikipedia.org
== General references == Colonial Reports. Aden Report: 1953 & 1954, HM Stationery Office 1956. Paul Dresch. A History of Modern Yemen. Cambridge, UK: Cambridge University Press, 2000. R.J. Gavin. Aden Under British Rule: 1839–1967. London: C. Hurst & Company, 1975. Gillian King. Imperial Outpost: Aden: Its Place in British Foreign Policy. Chatham House Essay Series, 1964. H. J. Liebensy. Administration and Legal Development in Arabia. Middle East Journal, 1955. Tom Little. South Arabia: Arena of Conflict. London: Pall Mall Press, 1968. Elizabeth Monroe. Kuwayt and Aden: A Contrast in British Policies. Middle East Journal, 1964. Newsinger, John (2012). British Counterinsurgency. London: Springer. ISBN 978-1137316868. E. H. Rawlings. The Importance of Aden. Contemporary Review, 195, 1959. Jonathan Walker. Aden Insurgency: The Savage War in South Arabia 1962–67, Spellmount, 2004. D. C. Watt. Labour Relations and Trade Unionism in Aden: 1952–60. Middle East Journal, 1962.
C6H5C(O)CH(NOSO2H) + 2 H2O → C6H5C(O)CHO + NH4HSO4 It may also be prepared from methyl benzoate by a reaction with potassium dimsyl to give an intermediate β-ketosulfoxide, which undergoes a Pummerer-type rearrangement, followed by oxidation by with copper(II) acetate. Alternatively, it can also be prepared by oxidation of acetophenone with selenium dioxide.
Franz Joseph was born on 18 August 1830 in the Schönbrunn Palace in Vienna (on the 65th anniversary of the death of Francis of Lorraine) as the eldest son of Archduke Franz Karl (the younger son of Francis I), and Sophie, Princess of Bavaria. Because his uncle, reigning from 1835 as the Emperor Ferdinand, was disabled by seizures, and his father unambitious and retiring, the mother of the young Archduke "Franzi" brought him up as a future emperor, with emphasis on devotion, responsibility and diligence. For this reason, Franz Joseph was consistently built up as a potential successor to the imperial throne by his politically ambitious mother from early childhood. Up to the age of 7, little "Franzi" was brought up in the care of the nanny ("Aja") Louise von Sturmfeder. Then the "state education" began, the central contents of which were "sense of duty", religiosity and dynastic awareness. The theologian Joseph Othmar von Rauscher conveyed to him the inviolable understanding of rulership of divine origin (divine grace), and therefore a belief that no participation of the population in rulership in the form of parliaments was required. The educators Heinrich Franz von Bombelles and Colonel Johann Baptist Coronini-Cronberg ordered Archduke Franz to study an enormous amount of time, which initially comprised 18 hours per week and was expanded to 50 hours per week by the age of 16.
Sources: en.wikipedia.org
== FGE-mechanism of cysteine-formylglycine conversion == The catalytic mechanism of FGE is well studied. A multistep redox reaction with a covalent enzyme: substrate intermediate is proposed. The role of the cysteine residue for the occurring conversion was studied by mutating the cysteine to alanine. No conversion was found using mass spectrometry when the mutated peptide tag was used. The mechanism shows the important role of the redox active thiol group of cysteine in the formation of f(Gly), as seen in Fig. 2. The key step of the catalytic cycle is the monooxidation of the cysteine residue of the enzyme, forming a reactive sulfenic acid intermediate. Subsequently, the hydroxyl group is transferred to the cysteine of the substrate and after hetero-analogous β-elimination of H2O, a thioaldehyde is formed. This compound is very reactive and easily hydrolyzed, releasing the aldehyde and a molecule of H2S,
=== Ion implantation === Ion implantation may be used to treat the surfaces of dielectric materials such as sapphire and silica to make composites with near-surface dispersions of metal or oxide nanoparticles.
Indirect discrimination is often structural, and this is seen in the gender pay gap of 21.7% across the Australian workforce, meaning women employees earn on average 78.3 cents compared to each $1 for male employees, according to the annual employer census. The main reasons for the gender pay gap are sex discrimination in child care and parental leave laws based on "persistent cultural norms that see women as more likely to undertake primary carer duties for children and family", "outright gender-based discrimination at work", "patterns of workforce engagement" and occupational segregation. Under the Fair Work Act 2009 section 302, employees, unions and the Sex Discrimination Commissioner can make an equal pay claim. The first post-2009 cases were brought by unions for social and community service workers, supported by the government. The Fair Work Commission interprets the appropriate comparator narrowly. Before 2009, the Librarians case, librarians were awarded a pay increase since the skill and education levels were comparable to better paid male-dominated industries. Structural discrimination also underlies much of the race pay gap in Australia. The first time Indigenous employees became legally entitled to equal pay with white workers, in cattle and farming jobs, was through a decision in 1966. The exclusion in the Conciliation and Arbitration Act 1904 section 4 for "persons engaged in domestic service" meant that many Indigenous women and girls employed as domestic staff were excluded.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.